News Industry Updates Medical Production Research
Abba Medix to produce new strains for veterans with PTSD

Abba Medix Corp.’s subsidiary, Canada House Wellness Group Inc., has acquired exclusive rights for two new strains designed for veterans suffering post-traumatic stress disorder (PTSD).

Canada House chief executive Chris Churchill-Smith said he hopes this acquisition will lead to a new line of cannabis products to help veterans manage their mental health.

“We are a veteran-focused company first and are committed to providing the highest quality genetics to our important registered patient base,” he said in a statement on June 4. “To this end, we very much look forward to sharing further news on the build out of our menu over the coming weeks and months.”

The strains, VetStar Day and VetStar Night, were developed by a cannabis research and development company in Lethbridge, Alta. called InPlanta Biotechnology Inc. The genetics were developed based on InPlanta’s 2013 research by Dr. Darryl Hudson, which observed that high THC Kush varieties with specific terpene profiles were effective in reducing symptoms of PTSD and pain. The study also found evidence that these strain types helped alleviate “hypervigilance syndrome,” which is a type of paranoia developed by soldiers who have fought in wars.

“These strains were bred and perfected over many years specifically for veterans,” said Dr. Igor Kovalchuk, Chief Science Officer of InPlanta. “As a company focused on the development of Cannabis varieties with maximum medicinal benefits, we are thrilled to be working alongside Chris and his team to bring these specifically designed Cannabis medications to those who need them the most.”

Kovalchuk, who is also CEO of Pathway Rx, is currently investigating cannabis as a potential treatment for COVID-19.

InPlanta selected both low and high myrcene varieties in order to create the “Veterans Day” and “Veterans Night” lines with reduced and enhanced sedative effects, respectively.

VetStar Day and VetStar Night are being grown in Abba’s licensed facility in Pickering, Ont. and are expected to be available for sale in September 2020 exclusively to patients registered with Abba.